‹ All Posts
CA Atin Agrrawal

3 mins ago · SEBI Registration INH000020785

buy on dips strategy to follow for investment purpose

TORNTPHARM Torrent Pharmaceuticals Limited is one of India's leading pharmaceutical companies and a part of the Torrent Group. The company has a strong presence in domestic and international pharmaceutical markets, with a focus on chronic and specialty therapies. Its major therapeutic segments include cardiovascular, central nervous system, gastrointestinal, diabetes and pain management. Torrent Pharma has established a strong position in the Indian pharmaceutical market through its established brands, distribution network and focus on research and development. Based on the available November 17 market data, the stock is trading below its short-term moving averages but above its 200-day moving average. Moving average Level 50-day DMA ₹4,749 100-day DMA ₹4,832 200-day DMA ₹4,554 This indicates near-term weakness, while the longer-term price structure remains relatively stronger as long as the stock sustains above its 200-day moving average. Important technical observations: - ₹4,550–₹4,575: Important support reference. - ₹4,700–₹4,750: Immediate resistance zone. - ₹4,830–₹4,850: Stronger resistance reference. - ₹5,000: Psychological resistance. A sustained move above ₹4,750 could improve short-term momentum. Conversely, a breakdown below ₹4,550 may increase selling pressure. SEBI Research Analyst Disclaimer This research commentary is prepared for informational and educational purposes only. It should not be construed as an assurance of returns or an individually tailored investment recommendation. Investments in securities are subject to market risks. Investors should read all relevant documents carefully and consult their financial advisor before making investment decisions. CA Atin Agrrawal SEBI Registered Research Analyst Registration No.: INH000020785 TIA – Trade India with Atin Share Market Ki Paathshaala

#FundamentalViews#TechnicalViews#WatchOutFor#EquityResearch#HiddenGems
TORNTPHARM_2026-11-17_17-49-01.png